UMB 425 is being called a breakthrough in the development of therapeutics to treat chronic pain, acts on two different opioid receptors with diminished tolerance over time and no obvious toxic effects.
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.
“UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain,” says Coop. “Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body’s development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief.”
For individuals living with chronic pain, either as a result of injury or disease such as arthritis, opioids are the standard treatment. But as the dosage increases to offset the body’s tolerance to their effects, opioids cause a number of adverse effects, including constipation, nausea, drowsiness, and dizziness. The unique dual-profile of UMB 425 – made possible through Coop’s collaborations with Alexander MacKerell, PhD, professor in PSC and director of the School’s Computer Aided Drug Design Center, and Maureen Kane, PhD, assistant professor in PSC and co-director of the School’s Mass Spectrometry Facility – provides both pain relief as well as diminished tolerance in one drug.
“Historically, medicinal chemists have developed drugs aimed at only one biological target,” says Coop. “However, two drugs administered together have the potential to metabolize differently in different individuals, as well as affect patients’ adherence to both drugs. A single compound that is able to provide both pain relief and diminished tolerance has the advantage of a defined ratio that we can optimize to ensure patients receive the maximum pain relief, while experiencing minimum adverse effects.”
Coop and his team conducted several in vitro and in vivostudies to determine the drug’s effectiveness in alleviating pain and diminishing tolerance over time. If future research and clinical trials are successful, UMB 425 could have a significant impact on the treatment and quality of life for individuals living with chronic pain.
“The clinical implication of this research has the potential to be tremendous,” says Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science, and an international authority in the fields of pain management and palliative care. “If clinicians can prescribe lower doses of opioids, they will not have to raise a patient’s dose because of tolerance to the analgesic effects. Using lower doses will result in less severe adverse effects for the patient, both short-term effects such as nausea and constipation, as well as long-term adverse effects on the endocrine and immunologic systems. This would be a highly significant advance in pain management.”
The Latest on: Chronic Pain
- Is Chronic Opioid Use Waning in Musculoskeletal Pain Patients? on December 17, 2018 at 2:11 pm
The risk for chronic opioid use decreased between 2008 and 2014 for patients with newly diagnosed pain in several musculoskeletal areas, indicating efforts to reduce opioid use have had some success, ... […]
- Pot Addicts Are Okay But Legitimate Chronic Pain Sufferers In Need of Opioids? Not So Much. on December 16, 2018 at 8:01 pm
Many states have limited the maximum dose as well. Federal opioid prescribing guidelines recommend doctors use caution in prescribing above 50 MME/day. But many patients need 90 MME/day or higher. […]
- Virginia Tech researchers collaborating with NIH to develop nonopioid drug for chronic pain on December 15, 2018 at 3:29 am
Researchers from the Virginia Tech School of Neuroscience are teaming with the University of California San Diego and the U.S. National Institutes of Health to develop a drug – now in its ... […]
- Chronic Back, Neck Pain? All You Might Need Is a Little Jab on December 14, 2018 at 7:39 am
When it comes to neck or back pain, just a little needle may do you. At least, that’s often the case for alleviating the chronic, gnawing pain caused by degenerating or damaged discs, says Kaliq Chang ... […]
- Young people suffering chronic pain battle isolation and stigma as they struggle to forge their identities on December 14, 2018 at 2:50 am
Adolescence can be a difficult but exciting time, when young people make discoveries and decisions about their futures, and develop a sense of who they are and their place in the world. But for ... […]
- Hidden Causes of Arthritis & Natural Solutions from Dr. Mark Wiley’s Book & Jesse Cannone Interview Podcasts on Chronic Pain on December 12, 2018 at 11:26 am
The slow progression of arthritis can be debilitating as joints begin to swell and sometimes become twisted as an autoimmune disorder causes the body to attacks joints and tissues. The other common ca... […]
- Researchers developing nonopioid drug for chronic pain on December 12, 2018 at 7:34 am
Ann Gregus and Matt Buczynski of the Virginia Tech School of Neuroscience Credit: Virginia Tech Researchers from the Virginia Tech School of Neuroscience are teaming with the University of ... […]
- Neurofeedback Procedure Relieves Chronic Pain in Fibro Patients on December 10, 2018 at 8:45 am
Neurofeedback is also known as electroencephalogram (EEG) biofeedback. It is a process that is based on electrical brain activity. It involves training the brain in which researchers can study how it ... […]
- Health Matters: Naturally Managing your Chronic Pain on December 10, 2018 at 6:38 am
Kat Stramara was born with chronic pain. “I was born with bone deformities, and throughout my life, I just thought everybody else had pain, so I never said anything growing up.” But a fall caused her ... […]
- How the Opioid Epidemic Affects Chronic Pain Patients on December 8, 2018 at 3:04 pm
“It is borderline genocide,” said DeLuca, 37. “You are allowing [chronic pain patients] to go home and essentially suffer until they kill themselves.” Last year, Lauren DeLuca went to the ... […]
via Google News and Bing News